Skandinaviska Enskilda Banken AB publ Sells 10,768 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Skandinaviska Enskilda Banken AB publ trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,005 shares of the biotechnology company's stock after selling 10,768 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.19% of United Therapeutics worth $30,044,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Axxcess Wealth Management LLC bought a new stake in United Therapeutics in the 3rd quarter worth about $435,000. Crossmark Global Holdings Inc. boosted its position in United Therapeutics by 20.4% in the third quarter. Crossmark Global Holdings Inc. now owns 3,584 shares of the biotechnology company's stock worth $1,284,000 after purchasing an additional 608 shares during the last quarter. Victory Capital Management Inc. grew its stake in United Therapeutics by 21.9% in the 3rd quarter. Victory Capital Management Inc. now owns 186,819 shares of the biotechnology company's stock valued at $66,947,000 after purchasing an additional 33,599 shares during the period. Oppenheimer & Co. Inc. increased its position in shares of United Therapeutics by 20.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 6,248 shares of the biotechnology company's stock valued at $2,239,000 after purchasing an additional 1,078 shares during the last quarter. Finally, Archer Investment Corp bought a new stake in shares of United Therapeutics during the 3rd quarter worth $283,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

UTHR has been the subject of several research reports. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $1.85 during trading hours on Friday, hitting $307.24. The company had a trading volume of 494,807 shares, compared to its average volume of 444,109. The firm has a market capitalization of $13.80 billion, a price-to-earnings ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The firm has a 50 day simple moving average of $349.77 and a 200 day simple moving average of $358.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period last year, the business earned $4.36 earnings per share. On average, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 116,464 shares of company stock valued at $42,396,244. 11.90% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.